MoneyWorks4Me

Cipla reports Profit after tax of Rs 3554.90 Mln, in the March 2023 quarter

26 Jul 2023 Evaluate
With no major difference for the quarter endedMarch 2023 , the total revenue stood at Rs. 38937.40  millions.The Company to register a -44.39%  fall in the net profit for the quarter ended March 2023.The company reported a degrowth in operating Profit to 9194.90 millions from 9415.70 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 38937.40 37345.90 4.26 157906.00 153808.20 2.66 157906.00 153808.20 2.66
Other Income 1197.10 3163.10 -62.15 4567.90 6667.00 -31.48 4567.90 6667.00 -31.48
PBIDT 9194.90 9415.70 -2.35 42493.70 43779.30 -2.94 42493.70 43779.30 -2.94
Interest 104.60 57.80 80.97 270.20 269.30 0.33 270.20 269.30 0.33
PBDT 7231.30 9357.90 -22.73 40364.50 43510.00 -7.23 40364.50 43510.00 -7.23
Depreciation 1615.80 1367.20 18.18 5959.10 5466.20 9.02 5959.10 5466.20 9.02
PBT 5615.50 7990.70 -29.72 34405.40 38043.80 -9.56 34405.40 38043.80 -9.56
TAX 2060.60 1598.60 28.90 9710.10 9218.00 5.34 9710.10 9218.00 5.34
Deferred Tax -385.80 -0.50 77060.00 -400.90 -276.90 44.78 -400.90 -276.90 44.78
PAT 3554.90 6392.10 -44.39 24695.30 28825.80 -14.33 24695.30 28825.80 -14.33
Equity 1614.30 1613.60 0.04 1614.30 1613.60 0.04 1614.30 1613.60 0.04
PBIDTM(%) 23.61 25.21 -6.34 26.91 28.46 -5.46 26.91 28.46 -5.46

Cipla Share Price

1426.90 -10.75 (-0.75%)
21-Aug-2026 11:06 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1893.90
Dr. Reddys Labs. 1177.90
Cipla 1426.90
Lupin 2199.75
Zydus Lifesciences 1108.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: